Bolt Biotherapeutics, Inc.
5.86+0.14 (+2.36%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · BOLT · USD
Key Stats
Market Cap
11.24MP/E (TTM)
-Basic EPS (TTM)
-26.42Dividend Yield
0%Recent Filings
8-K
Workforce cut extends cash runway
Bolt Biotherapeutics kicked off a restructuring on October 1, 2025, slashing its workforce by 50% to curb expenses and stretch cash into 2027. This pairs with a Phase 1 update for BDC-4182, showing strong immune responses at low doses, prompting step-up dosing tweaks that delay initial data to Q3 2026. The move prioritizes clinical progress amid tough markets. Charges will hit $1.5-2.0 million in Q4 2025.
8-K
Bolt Q2 results and pipeline update
Bolt Biotherapeutics reported Q2 2025 results, slashing R&D expenses to $7.5 million from $15.4 million last year after discontinuing BDC-1001, while collaboration revenue rose to $1.8 million. The company advanced BDC-4182 into Phase 1 for gastric cancers, with initial data due in H1 2026, and seeks a partner for BDC-3042 following a partial response in lung cancer patients. Cash stands at $48.5 million, funding operations through mid-2026. A 1:20 reverse stock split in June regained Nasdaq compliance.
10-Q
Q2 FY2025 results
Bolt Biotherapeutics narrowed its Q2 net loss to $8.6 million from $21.2 million a year earlier, thanks to slashed R&D spending after axing a program and halving staff. Collaboration revenue climbed 42% year-over-year to $1.8 million, fueled by Genmab work, while six-month revenue dipped to $3.0 million from $6.5 million due to the Innovent deal's wind-down. Operating expenses plunged 54% to $11.0 million, with R&D down 51% to $7.5 million and G&A off 28% to $3.5 million. Cash burn eased, leaving $48.5 million in cash and investments to stretch into mid-2026. The reverse stock split in June tidied up the share count. Restructuring wrapped with $39,000 left to pay. Yet supply chain snarls from global trade tensions could hike costs and slow trials.
8-K
1:20 reverse stock split executed
Bolt Biotherapeutics executed a 1:20 reverse stock split on June 6, 2025, consolidating every 20 shares into one to maintain Nasdaq compliance. This adjustment reduces outstanding shares while preserving par value at $0.00001, with trading on a split-adjusted basis starting June 9 under ticker BOLT. No fractional shares issued; cash payments cover them instead. Yet the move underscores ongoing liquidity pressures.
8-K
Bolt enacts 1:20 reverse split
Bolt Biotherapeutics approved a 1-for-20 reverse stock split, effective June 6, 2025, to consolidate shares and boost the per-share price. This move, ratified by shareholders on May 27, follows board selection of the ratio that day. No fractional shares issued; cash payouts instead. Trading resumes split-adjusted on Nasdaq under BOLT on June 9. It aims to maintain listing compliance.
BCTX
BriaCell Therapeutics Corp.
12.44-0.90
BNTX
BioNTech SE
103.35-1.68
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
CLDI
Calidi Biotherapeutics, Inc.
1.49-0.03
FATE
Fate Therapeutics, Inc.
1.34-0.15
IMTX
Immatics N.V.
10.34-0.02
MRKR
Marker Therapeutics, Inc.
0.97-0.04
NWBO
Northwest Biotherapeutics, Inc.
0.23-0.02
RENB
Lunai Bioworks Inc.
1.42+0.00
SNSE
Sensei Biotherapeutics, Inc.
9.38-0.24